OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group
This article was originally published in The Tan Sheet
FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group
You may also be interested in...
Non-retail distributors of pseudoephedrine, phenylpropanolamine and combination ephedrine products would be required to pay the full amount of Drug Enforcement Administration registration fees, under a proposed rule published in the Federal Register Nov. 16
FDA should re-word a cardiovascular warning statement it has proposed for OTC bronchodilator products because the statement is "unnecessarily alarming" and "goes beyond that which is supported by data," Wyeth Consumer Healthcare maintains
Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register